Saracatinib

DB11805InvestigationalSmall molecule

Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1 and Proto-oncogene tyrosine-protein kinase Src
Curator reviewed
Formula / weight: C₂₇H₃₂ClN₅O₅ · 542.026 g/mol (avg)
Code names: AZD-0530

Resolves to

Compound

Structure

InChIKeyOUKYUETWWIPKQR-UHFFFAOYSA-NSMILESCN1CCN(CCOC2=CC3=C(C(NC4=C(Cl)C=CC5=C4OCO5)=NC=N3)C(OC3CCOCC3)=C2)CC1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

241Drug interactionsStructured to mechanism, not free text

33Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Saracatinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.